Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
NCT ID: NCT06772168
Last Updated: 2026-01-15
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE3
Total Enrollment
240 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-04-19
Study Completion Date
2027-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this clinical trial is to learn if drug CMG190303 to treat Type 2 Diabetes and Dyslipidemia in adults. It will also learn about the safety of CMG190303. The main questions it aims to answer are:
-Primary Objectives:
1. To compare the change in HbA1c from baseline to 24 weeks between CMG190303 and Rosuvastatin
2. To compare the change in LDL-C from baseline to 24 weeks between CMG190303 and Dapagliflozin
-Primary Objectives:
1. To compare the change in HbA1c from baseline to 24 weeks between CMG190303 and Rosuvastatin
2. To compare the change in LDL-C from baseline to 24 weeks between CMG190303 and Dapagliflozin
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus
NCT00376181
Type 2 Diabetes
TERMINATED
PHASE3
Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
NCT01646320
Type 2 Diabetes
COMPLETED
PHASE3
Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes
NCT00116831
Atherosclerosis
COMPLETED
PHASE3
Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes
NCT01606007
Type 2 Diabetes
COMPLETED
PHASE3
Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia
NCT00331487
Diabetes Mellitus
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Dyslipidemia
Type 2 Diabetes
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CMG190303(Dapagliflozin/Rosuvastatin)
Group Type
EXPERIMENTAL
CMG190303(Dapagliflozin/Rosuvastatin)
Intervention Type
DRUG
0-8 week: Dapagliflozin 10mg and Rosuvastatin 5mg 8-16 week: Dapagliflozin 10mg and Rosuvastatin 10mg 16-24 week: Dapagliflozin 10mg and Rosuvastatin 20mg
Comparator 1: Dapagliflozin/Rosuvastatin placebo
Group Type
PLACEBO_COMPARATOR
Comparator 1: Dapagliflozin/Rosuvastatin placebo
Intervention Type
DRUG
0-24 week: Dapagliflozin 10mg and Rosuvastatin placebo
Comparator 2: Rosuvastatin/Dapagliflozin placebo
Group Type
PLACEBO_COMPARATOR
Rosuvastatin/Dapagliflozin placebo
Intervention Type
DRUG
0-8 week: Dapagliflozin placebo and Rosuvastatin 5mg 8-16 week: Dapagliflozin placebo and Rosuvastatin 10mg 16-24 week: Dapagliflozin placebo and Rosuvastatin 20mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CMG190303(Dapagliflozin/Rosuvastatin)
0-8 week: Dapagliflozin 10mg and Rosuvastatin 5mg 8-16 week: Dapagliflozin 10mg and Rosuvastatin 10mg 16-24 week: Dapagliflozin 10mg and Rosuvastatin 20mg
Intervention Type
DRUG
Comparator 1: Dapagliflozin/Rosuvastatin placebo
0-24 week: Dapagliflozin 10mg and Rosuvastatin placebo
Intervention Type
DRUG
Rosuvastatin/Dapagliflozin placebo
0-8 week: Dapagliflozin placebo and Rosuvastatin 5mg 8-16 week: Dapagliflozin placebo and Rosuvastatin 10mg 16-24 week: Dapagliflozin placebo and Rosuvastatin 20mg
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. A male or female adult aged between 19 and 80 in South Korea
2. An individual with type II diabetes and dyslipidemia
3. An individual meeting any of the followings at the time of the screening
1. Metformin monotherapy: An individual who was on a stable dose of metformin ≥1,000 mg/day as monotherapy for at least 6 weeks prior to screening (for a patient who took a dyslipidemia treatment within 4 weeks from the screening, the patient had to be on a stable dose of metformin ≥1,000 mg/day as monotherapy for at least 2 weeks prior to the screening)
2. Dual combination therapy: An individual who was on a stable dose of metformin ≥1,000 mg/day for at least 1 week prior to the screening in combination with additional oral diabetes treatment (DPP-4i, TZD, SU)
4. An individual meeting the following criteria for HbA1c at the time of the screening
1. Metformin monotherapy: An individual with 7.0% ≤ HbA1c ≤ 10.5% whose blood sugar level is not adequately controlled
2. Dual combination therapy: An individual with 6.5% ≤ HbA1c ≤ 10% whose blood sugar level is not adequately controlled
5. An individual with FPG (Fasting Plasma Glucose) ≤ 270 mg/dL at the time of the screening
6. A patient who did not take a dyslipidemia treatment within 4 weeks from the screening and whose fasting serum lipid test level is 100 mg/dL ≤ LDL-C ≤ 250 mg/dL and TG ≤ 400 mg/dL
7. A patient who took a dyslipidemia treatment within 4 weeks from the screening and was on monotherapy of a statin-class drug as a dyslipidemia treatment for at least 6 weeks prior to the screening (an individual who took omega-3 alone or omega-3 in combination with a statin-class drug is considered to have taken the monotherapy of a statin drug as described here)
8. An individual who voluntarily consented to participating in the clinical study and signed the informed consent form
1. An individual who continuously took metformin ≥1,000 mg/day before the randomization (after the screening visit (Visit 1)) and underwent the wash-out period, TLC and run-in period as described below
1. An individual who took metformin monotherapy but did not take a dyslipidemia treatment: An individual who underwent the TLC for 2 weeks and the TLC and placebo run-in period at the same time for 2 weeks
2. An individual who took metformin monotherapy and took a dyslipidemia treatment: An individual who underwent the wash-out period for at least 4 weeks, the TLC for 2 weeks, and the TLC and placebo run-in period at the same time for 2 weeks
3. An individual who took a dual combination therapy of an oral diabetes treatment other than metformin and did not take a dyslipidemia treatment: An individual who underwent the wash-out period for at least 6 weeks, the TLC for 2 weeks, and the TLC and placebo run-in period at the same time for 2 weeks
4. An individual who took a dual combination therapy of an oral diabetes treatment other than metformin and took a dyslipidemia treatment: An individual who underwent the wash-out period for at least 6 weeks, the TLC for 2 weeks, and the TLC and placebo run-in period at the same time for 2 weeks
2. An individual with 7.0% ≤ HbA1c ≤ 10.5% based on the central laboratory test on a visit 1-4 (Run-in visit)
3. An individual with FPG (Fasting Plasma Glucose) ≤ 270 mg/dL based on the central laboratory test on a visit 1-4 (Run-in visit)
4. An individual whose fasting serum lipid test level is 100 mg/dL ≤ LDL-C ≤ 250 mg/dL and TG ≤ 400 mg/dL based on the central laboratory test on a visit 1-4 (Run-in visit)
5. An individual with medication compliance of 70% or higher during the run-in period
2. An individual with type II diabetes and dyslipidemia
3. An individual meeting any of the followings at the time of the screening
1. Metformin monotherapy: An individual who was on a stable dose of metformin ≥1,000 mg/day as monotherapy for at least 6 weeks prior to screening (for a patient who took a dyslipidemia treatment within 4 weeks from the screening, the patient had to be on a stable dose of metformin ≥1,000 mg/day as monotherapy for at least 2 weeks prior to the screening)
2. Dual combination therapy: An individual who was on a stable dose of metformin ≥1,000 mg/day for at least 1 week prior to the screening in combination with additional oral diabetes treatment (DPP-4i, TZD, SU)
4. An individual meeting the following criteria for HbA1c at the time of the screening
1. Metformin monotherapy: An individual with 7.0% ≤ HbA1c ≤ 10.5% whose blood sugar level is not adequately controlled
2. Dual combination therapy: An individual with 6.5% ≤ HbA1c ≤ 10% whose blood sugar level is not adequately controlled
5. An individual with FPG (Fasting Plasma Glucose) ≤ 270 mg/dL at the time of the screening
6. A patient who did not take a dyslipidemia treatment within 4 weeks from the screening and whose fasting serum lipid test level is 100 mg/dL ≤ LDL-C ≤ 250 mg/dL and TG ≤ 400 mg/dL
7. A patient who took a dyslipidemia treatment within 4 weeks from the screening and was on monotherapy of a statin-class drug as a dyslipidemia treatment for at least 6 weeks prior to the screening (an individual who took omega-3 alone or omega-3 in combination with a statin-class drug is considered to have taken the monotherapy of a statin drug as described here)
8. An individual who voluntarily consented to participating in the clinical study and signed the informed consent form
1. An individual who continuously took metformin ≥1,000 mg/day before the randomization (after the screening visit (Visit 1)) and underwent the wash-out period, TLC and run-in period as described below
1. An individual who took metformin monotherapy but did not take a dyslipidemia treatment: An individual who underwent the TLC for 2 weeks and the TLC and placebo run-in period at the same time for 2 weeks
2. An individual who took metformin monotherapy and took a dyslipidemia treatment: An individual who underwent the wash-out period for at least 4 weeks, the TLC for 2 weeks, and the TLC and placebo run-in period at the same time for 2 weeks
3. An individual who took a dual combination therapy of an oral diabetes treatment other than metformin and did not take a dyslipidemia treatment: An individual who underwent the wash-out period for at least 6 weeks, the TLC for 2 weeks, and the TLC and placebo run-in period at the same time for 2 weeks
4. An individual who took a dual combination therapy of an oral diabetes treatment other than metformin and took a dyslipidemia treatment: An individual who underwent the wash-out period for at least 6 weeks, the TLC for 2 weeks, and the TLC and placebo run-in period at the same time for 2 weeks
2. An individual with 7.0% ≤ HbA1c ≤ 10.5% based on the central laboratory test on a visit 1-4 (Run-in visit)
3. An individual with FPG (Fasting Plasma Glucose) ≤ 270 mg/dL based on the central laboratory test on a visit 1-4 (Run-in visit)
4. An individual whose fasting serum lipid test level is 100 mg/dL ≤ LDL-C ≤ 250 mg/dL and TG ≤ 400 mg/dL based on the central laboratory test on a visit 1-4 (Run-in visit)
5. An individual with medication compliance of 70% or higher during the run-in period
Exclusion Criteria
1. A patient with hypersensitivity to the active ingredient (dapagliflozin or rosuvastatin) or any component of the investigational product
2. A pregnant woman, a breastfeeding woman, or a woman of childbearing potential or a man who does not agree to use an appropriate contraceptive method\* during the clinical study
\*: a. Implantation of an intrauterine device or intrauterine system, b. Dual barrier method for men or women of childbearing potential (condom and contraceptive vaginal diaphragm, vaginal sponge or cervical cap), c. Sterilization (vasectomy, bilateral tubal ligation, etc.)
3. A patient with the body mass index (BMI) \< 15 kg/m2 or \> 40 kg/m2
4. An individual with the following medical history or laboratory test abnormality
1. A patient with type I diabetes or secondary diabetes or severe diabetes complications
2. A patient with metabolic acidosis such as diabetic ketoacidosis
3. A patient with acute arterial disease at the time of screening (e.g., a patient with a medical history of unstable angina, myocardial infarction, transient ischemic attack, cerebrovascular disease, coronary artery bypass graft, or coronary intervention within 3 months prior to entry to the study)
4. A patient with a medical history of severe heart failure (NYHA class III to IV), severe heart valve disease, severe obstructive/hypertrophic myocardial disease, severe obstructive coronary artery disease, abdominal aneurysm, or uncontrolled arrhythmia, that occurred within 24 weeks prior to the screening
5. A patient with uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg) or hypotension (systolic blood pressure \< 90 mmHg or diastolic blood pressure \< 60 mmHg)
6. An individual with uncontrolled thyroid dysfunction (TSH (Thyroid Stimulating Hormone) ≥ 1.5 X ULN, or an inability to maintain a stable TSH level in the opinion of the investigator)
7. An individual with a medical history of myopathy, including rhabdomyolysis, or whose CK is 2 times or higher the upper limit of normal range of CK
8. A patient with severe renal impairment (eGFR \< 45 mL/min/1.73 m2 for a patient taking metformin at 1,000 mg, or eGFR \< 60 mL/min/1.73 m2 for a patient taking metformin at \> 1,000 mg) or hepatic impairment (AST or ALT is 2.5 times the upper limit of normal range)
9. An individual with a past history of drug addiction or alcoholism within 1 year from the screening
10. An individual with major psychiatric disease: Schizophrenia, mood disorder (depression, bipolar disorder), anxiety disorder, obsessive disorder, eating disorder, personality disorder, etc.
11. Pancreatitis or pancreatic surgery
12. Urinary tract infection, reproductive system infection (including fungal infection) or urination disorder (exceptionally, an individual who has no urination disorder symptom due to drug treatment, etc. may be enrolled) within 24 weeks from the screening
13. An individual with a history of a surgery to treat obesity or a gastrointestinal surgery, or a gastrointestinal disorder that impairs drug absorption
14. A patient with a genetic problem such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
15. An individual in whom a malignancy occurred within 5 years from the screening (exceptionally, an individual who was assessed to have achieved complete response after treatment and did not experience recurrence within at least 2 years from the screening or, regarding basal cell carcinoma, skin epithelial squamous cell cancer, thyroid cancer or intraepithelial carcinoma in other sites, an individual, even with a medical history of the aforementioned cancer within 5 years, who was successfully treated and did not experience recurrence for at least 3 years, may be enrolled depending on the opinion of the investigator)
5. An individual with a history of administering any of the following drugs within 3 months prior to the screening
1. Insulin injection (exceptionally, an individual who temporarily (for not longer than 14 days) was administered insulin due to surgery or examination may be included) or GLP-1 analogue
2. Weight control drugs or, in the opinion of the investigator, drugs that may significantly affect weight control
3. Cyclosporin
6. An individual who has a history of administering a systemic steroid agent within 2 weeks from the screening and requires administration of a systemic steroid agent during the clinical study
7. An individual who is scheduled to have an examination using an iodine contrast agent, or is contraindicated to use of metformin due to acute and chronic metabolic acidosis, etc.
8. An individual who is expected to use a 7.6.1 prohibited concomitant drug during the clinical study, including the screening (use of any prescription drugs and over-the-counter drugs, including prohibited concomitant drugs, must be discussed with the investigator prior to use)
9. A patient who participated in another clinical study and used/applied another investigational product and medical device within 3 months (exceptionally, a patient who participated in a non-interventional observation study may participate in the present study)
10. A patient otherwise considered ineligible for participation in the clinical study in the opinion of the investigator
2. An individual who does not fall under the above condition but is otherwise considered ineligible in the opinion of the investigator
2. A pregnant woman, a breastfeeding woman, or a woman of childbearing potential or a man who does not agree to use an appropriate contraceptive method\* during the clinical study
\*: a. Implantation of an intrauterine device or intrauterine system, b. Dual barrier method for men or women of childbearing potential (condom and contraceptive vaginal diaphragm, vaginal sponge or cervical cap), c. Sterilization (vasectomy, bilateral tubal ligation, etc.)
3. A patient with the body mass index (BMI) \< 15 kg/m2 or \> 40 kg/m2
4. An individual with the following medical history or laboratory test abnormality
1. A patient with type I diabetes or secondary diabetes or severe diabetes complications
2. A patient with metabolic acidosis such as diabetic ketoacidosis
3. A patient with acute arterial disease at the time of screening (e.g., a patient with a medical history of unstable angina, myocardial infarction, transient ischemic attack, cerebrovascular disease, coronary artery bypass graft, or coronary intervention within 3 months prior to entry to the study)
4. A patient with a medical history of severe heart failure (NYHA class III to IV), severe heart valve disease, severe obstructive/hypertrophic myocardial disease, severe obstructive coronary artery disease, abdominal aneurysm, or uncontrolled arrhythmia, that occurred within 24 weeks prior to the screening
5. A patient with uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg) or hypotension (systolic blood pressure \< 90 mmHg or diastolic blood pressure \< 60 mmHg)
6. An individual with uncontrolled thyroid dysfunction (TSH (Thyroid Stimulating Hormone) ≥ 1.5 X ULN, or an inability to maintain a stable TSH level in the opinion of the investigator)
7. An individual with a medical history of myopathy, including rhabdomyolysis, or whose CK is 2 times or higher the upper limit of normal range of CK
8. A patient with severe renal impairment (eGFR \< 45 mL/min/1.73 m2 for a patient taking metformin at 1,000 mg, or eGFR \< 60 mL/min/1.73 m2 for a patient taking metformin at \> 1,000 mg) or hepatic impairment (AST or ALT is 2.5 times the upper limit of normal range)
9. An individual with a past history of drug addiction or alcoholism within 1 year from the screening
10. An individual with major psychiatric disease: Schizophrenia, mood disorder (depression, bipolar disorder), anxiety disorder, obsessive disorder, eating disorder, personality disorder, etc.
11. Pancreatitis or pancreatic surgery
12. Urinary tract infection, reproductive system infection (including fungal infection) or urination disorder (exceptionally, an individual who has no urination disorder symptom due to drug treatment, etc. may be enrolled) within 24 weeks from the screening
13. An individual with a history of a surgery to treat obesity or a gastrointestinal surgery, or a gastrointestinal disorder that impairs drug absorption
14. A patient with a genetic problem such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
15. An individual in whom a malignancy occurred within 5 years from the screening (exceptionally, an individual who was assessed to have achieved complete response after treatment and did not experience recurrence within at least 2 years from the screening or, regarding basal cell carcinoma, skin epithelial squamous cell cancer, thyroid cancer or intraepithelial carcinoma in other sites, an individual, even with a medical history of the aforementioned cancer within 5 years, who was successfully treated and did not experience recurrence for at least 3 years, may be enrolled depending on the opinion of the investigator)
5. An individual with a history of administering any of the following drugs within 3 months prior to the screening
1. Insulin injection (exceptionally, an individual who temporarily (for not longer than 14 days) was administered insulin due to surgery or examination may be included) or GLP-1 analogue
2. Weight control drugs or, in the opinion of the investigator, drugs that may significantly affect weight control
3. Cyclosporin
6. An individual who has a history of administering a systemic steroid agent within 2 weeks from the screening and requires administration of a systemic steroid agent during the clinical study
7. An individual who is scheduled to have an examination using an iodine contrast agent, or is contraindicated to use of metformin due to acute and chronic metabolic acidosis, etc.
8. An individual who is expected to use a 7.6.1 prohibited concomitant drug during the clinical study, including the screening (use of any prescription drugs and over-the-counter drugs, including prohibited concomitant drugs, must be discussed with the investigator prior to use)
9. A patient who participated in another clinical study and used/applied another investigational product and medical device within 3 months (exceptionally, a patient who participated in a non-interventional observation study may participate in the present study)
10. A patient otherwise considered ineligible for participation in the clinical study in the opinion of the investigator
2. An individual who does not fall under the above condition but is otherwise considered ineligible in the opinion of the investigator
Minimum Eligible Age
19 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CMG Pharmaceutical Co. Ltd
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hallym university sungsim medical center
Anyang, , South Korea
Site Status
RECRUITING
Buchon sejong hospital
Buchon, , South Korea
Site Status
RECRUITING
Inje university heaundea paik hospital
Busan, , South Korea
Site Status
RECRUITING
Soonchunhyang cheonan university hospital
Cheonan, , South Korea
Site Status
RECRUITING
Keimyung University Dongsan Medical Center
Daegu, , South Korea
Site Status
RECRUITING
Daejeon eulji medical center, eulji university
Daejeon, , South Korea
Site Status
RECRUITING
Myongji Hospital
Goyang-si, , South Korea
Site Status
RECRUITING
Hanyang University Medical Center
Guri-si, , South Korea
Site Status
RECRUITING
Chosun University Hospital
Gwangju, , South Korea
Site Status
RECRUITING
Wonkwang university hospital
Iksan, , South Korea
Site Status
RECRUITING
Inha university hospital
Inchon, , South Korea
Site Status
RECRUITING
Chonbuk National University Hospital
Jeonju, , South Korea
Site Status
RECRUITING
Bundang CHA medical center
Seongnam, , South Korea
Site Status
RECRUITING
Seoul National University Bundang Hospital
Seongnam, , South Korea
Site Status
RECRUITING
Nowon eulji medical center, eulji university
Seoul, , South Korea
Site Status
RECRUITING
Korea University ANAM Hospital
Seoul, , South Korea
Site Status
RECRUITING
Severance hospital
Seoul, , South Korea
Site Status
RECRUITING
Kyung hee university hospital at gangdong
Seoul, , South Korea
Site Status
RECRUITING
The Catholic University of Korea, Seoul ST. Mary's Hospital
Seoul, , South Korea
Site Status
RECRUITING
Hallym university gangnam medical center
Seoul, , South Korea
Site Status
RECRUITING
Korea University Guro Hospital
Seoul, , South Korea
Site Status
RECRUITING
Ajou University Hospital
Suwon, , South Korea
Site Status
RECRUITING
Wonju serverance christian hospital
Wŏnju, , South Korea
Site Status
RECRUITING
Yongin Severance Hospital
Yongin-si, , South Korea
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
South Korea
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CMG1903-104
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects
NCT00499707
COMPLETED
PHASE3
Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure
NCT00521820
TERMINATED
PHASE3
Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)
NCT03074630
COMPLETED
PHASE4
Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
NCT01210001
COMPLETED
PHASE3
Dyslipidemia in Type 2 Diabetes (0767-034)
NCT00547274
TERMINATED
PHASE3
A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics
NCT00067951
COMPLETED
PHASE3
Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
NCT06290349
ACTIVE_NOT_RECRUITING
PHASE3
Evaluation of Dapagliflozin Taken Twice-daily
NCT01217892
COMPLETED
PHASE3
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
NCT01042977
COMPLETED
PHASE3
Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
NCT04356742
COMPLETED
PHASE3
A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
NCT07082114
RECRUITING
PHASE3
Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate
NCT00551564
COMPLETED
PHASE1
To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
NCT06578676
RECRUITING
PHASE1
Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
NCT03097107
SUSPENDED
PHASE2
Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin
NCT03608358
TERMINATED
PHASE3
A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
NCT04885712
COMPLETED
PHASE3
Phase III Insulin Add-On Asia Regional Program - ST
NCT02096705
COMPLETED
PHASE3
SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
NCT05782192
COMPLETED
PHASE3
A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator
NCT00760578
COMPLETED
PHASE2
The Effect of Pioglitazone and Rosiglitazone on Atherosclerotic and Inflammatory Markers in Patients With Metabolic Syndrome
NCT00314561
COMPLETED
PHASE4
A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus
NCT00661921
WITHDRAWN
PHASE2
Rosiglitazone And Plaque Study for Type 2 Diabetes Mellitus
NCT00231387
COMPLETED
PHASE3
Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety
NCT05915949
UNKNOWN
PHASE4
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
NCT07303803
NOT_YET_RECRUITING
PHASE2